Hormones
A two-amino-acid peptide from Russian research, studied for bladder and urinary function in aging. Human evidence is still thin.
Start here
Vesilute is a two-amino-acid peptide bioregulator (Glu-Asp) studied for supporting bladder and prostate health. Research describes reduced inflammation in urogenital tissue and improved bladder muscle tone, including better bladder capacity and fewer urgency episodes in clinical assessments of overactive bladder. It is a research compound, not FDA approved, taken by mouth, under the tongue, or by injection.
Vesilute is a mixture of nucleotide and nucleoside compounds derived from cow brain tissue that support cell energy production and repair. It works by providing the building blocks and energy molecules that cells need to recover from damage, making it useful for treating stroke and traumatic brain injuries. It helps restore normal brain function by improving blood flow and cell metabolism.
Vesilute is a mix of nucleotides (ATP, GTP, CTP, UTP, the energy carriers and building blocks of cells), nucleosides (adenosine, guanosine, cytidine, uridine), free nucleobases, and related breakdown products, all taken from cow brain tissue. Cells can use these directly to make ATP (the cell's energy molecule) through a salvage pathway (a recycling route run by enzymes called nucleoside kinases). This skips the de novo pathway (building from scratch), which costs much more energy. Nucleosides cross the blood-brain barrier (the filter that protects the brain) using transporter proteins (the CNT and ENT families), so they can reach the central nervous system. Inside nerve cells and glial cells (the brain's support cells), kinase enzymes (deoxynucleotide kinase and nucleoside kinase) turn nucleosides into nucleotides, which rebuilds ATP stores. These compounds also act as signals. They bind P1 (adenosine) and P2 (ATP/ADP) purinergic receptors (docking points for these molecules) on nerve and glial cell surfaces, which switches on protective pathways. Vesilute improves blood flow in the brain by widening vessels through adenosine receptors. It lowers damage to nerve cells from low blood supply by blocking P2Y-receptor-driven calcium overload (a flood of calcium that overexcites and kills nerve cells). The preparation also supplies raw material for making DNA and RNA, which supports nerve cell adaptability and protein production during recovery.
Evidence check
Some human studies
It has been tested in people, but only in small or early-stage studies. Promising, but not yet proven the way an approved medicine is.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Bladder Health
Vesilute helps your bladder muscles work better, reducing urgent bathroom trips and improving how much your bladder can comfortably hold.
Prostate Support
This peptide calms inflammation in prostate tissue and helps cells repair themselves, which may ease symptoms of an enlarged prostate.
Tissue Repair
Vesilute turns on repair genes in aging urinary tract cells, helping worn-out tissues heal and work like they did when younger.
The most-asked question
The research-reported range is 2 capsules, once daily. Studies used different doses for different situations — find yours:
Urinary/urogenital research, First-time users
1 capsule (10 mg) once daily
Khavinson ED (Glu-Asp) urogenital dipeptide bioregulator; absorbed intact via PepT1 transporter 6. Research/wellness use, not FDA-approved.
Urogenital support, Cyclical protocols
2 capsules (20 mg) daily
Standard daily dose; courses repeated every 2–6 months 6. Sublingual administration also used for buccal uptake.
Intensive urogenital research protocols
10–20 mg per week (split into 2–3 injections)
Injectable practice protocol for direct systemic (affecting the whole body) delivery of the ED dipeptide 6. Research use only.
The ceiling: 40 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Vesilute:
Vesilute comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Vesilute exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Vesilute's recorded schedule.
Injection sites & technique
Vesilute is taken by mouth (capsule or tablet)—no injection required
Timing
Take Vesilute at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
Vesilute can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
Vesilute should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Slight nausea or stomach upset with oral administration, common with peptide supplements. Usually transient and self-limiting.
What to do Take with a small amount of food or water. Usually resolves within the first few days.
Temporary increase in urination frequency during the first few days as bladder smooth muscle tone normalizes and detrusor function adjusts.
What to do Normal part of the therapeutic process. Should stabilize within 5-7 days as bladder function normalizes.
A short-lived headache while your body adjusts. It may come from changes in how tight your blood vessels are as endothelin-1 (a vessel-tightening chemical) returns to normal.
What to do Ensure adequate hydration. Usually self-limiting within 3-5 days. Standard analgesics may be used if needed.
Slight tiredness or drowsiness in the first few days as your body adapts to changes in which genes are active.
What to do Take in the morning. Usually resolves as the body adjusts to the bioregulatory effects.
Worth knowing about, but most people never see these.
Slight irritation, redness, or mild soreness at the injection site when administered parenterally (subcutaneous (under the skin) or intramuscular (into a muscle)).
What to do Rotate injection sites. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.
Rare, but if any of these happen, stop and contact a medical professional.
No serious adverse effects have been reported across 30+ years of Khavinson bioregulator use in over 15 million individuals. The ultra-short dipeptide structure and physiological amino acid composition contribute to the excellent safety profile.
What to do As with any supplement, discontinue and consult a healthcare provider if unexpected reactions occur.
Week by week
Is it right for you?
Vesilute should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Vesilute. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin. Limited systemic (affecting the whole body) absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature. Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Safety information comes from cosmetic ingredient safety testing (INCI approved), manufacturer safety dossiers, and post-market surveillance in over 500 topical formulations globally. Minimal human clinical trial data exist specifically for efficacy in anti-aging applications, but extensive use in cosmetics establishes acceptable topical safety profile. Non-systemic (affecting the whole body) bioavailability (how much actually gets absorbed and used) through skin means serious adverse events are inherently unlikely despite lack of formal drug-level safety studies.
Keeping it good
Store Vesilute in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Vesilute should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2023
This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Linkova N, Khavinson V, Diatlova A
2020
This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Ashapkin V, Khavinson V, Shilovsky G
2016
This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Lin'kova NS, Drobintseva AO, Orlova OA
2021
This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Khavinson VK, Lin'kova NS, Umnov RS
2016
This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Kozlov KL, Bolotov II, Linkova NS
2024
Peptide Database (Khavinson urogenital bioregulator reference)
If this isn't the right fit
Your questions
Vesilute is a synthetic dipeptide consisting of glutamic acid and aspartic acid (Glu-Asp or ED), developed by Professor Vladimir Khavinson as a tissue-specific bioregulator for the urogenital system. It specifically targets the bladder and prostate, normalizing smooth muscle function, reducing chronic inflammation, and supporting tissue repair. The Glu-Asp sequence was identified as the minimal bioactive unit responsible for the urogenital-specific effects observed with larger peptide extracts from these tissues.
Even though it is tiny, Vesilute's Glu-Asp dipeptide (a two-amino-acid peptide) attaches directly to DNA at specific spots (the GGAG sequence in B-form DNA). That changes how open the DNA is and how genes are read, at nanomolar concentrations (extremely tiny amounts). This gene-level effect, confirmed by molecular docking studies (computer models of how molecules fit together), lets even the smallest bioregulator peptides have effects specific to certain tissues. Its ultra-short size also helps it enter cells through peptide transporters (PepT1, gateways for small peptides), reach the nucleus without a carrier, and resist some protein-cutting enzymes. That makes it one of the best-absorbed peptide bioregulators in the Khavinson family.
A prospective clinical study evaluating Vesilute in 20 women with overactive bladder syndrome demonstrated statistically significant improvements in maximum cystometric capacity, detrusor overactivity parameters, urgency episodes, and micturition frequency using objective urodynamic measurements. Additional clinical trials in Russia have shown benefits for BPH symptom management including improved urinary flow rates and symptom scores. However, these studies were conducted in Russian clinical settings and have not been replicated in Western randomized controlled trials.
Vesilute (ED) shares the Glu-Asp core sequence with several related Khavinson bioregulators: Pinealon (EDR — brain/pineal), Chonluten (EDG — gastrointestinal), and the longer Prostamax (KDGP — prostate). This shared ED core suggests a common DNA-binding mechanism with tissue specificity determined by the additional amino acids. In Khavinson's framework, each organ has an optimal peptide bioregulator, and using complementary peptides in rotation provides comprehensive anti-aging support. Vesilute is often combined with Prostamax for prostate-specific protocols.
The Khavinson peptide bioregulator class has an extensive safety record spanning over 30 years and 15 million patients across Russia and Eastern Europe, with no reported serious adverse effects. Vesilute's safety profile benefits from its composition of just two naturally occurring amino acids (glutamic acid and aspartic acid), which are readily metabolized through standard amino acid pathways. The standard approach involves cyclical treatment courses (20-30 days) with 2-6 month intervals, rather than continuous daily use. No drug dependence, allergic reactions, or systemic (affecting the whole body) toxicity has been documented.
Do not treat Vesilute as a replacement for established BPH (enlarged prostate) medicines such as alpha-1 blockers (tamsulosin) or 5-alpha-reductase inhibitors (finasteride) without medical guidance. It works in a very different way: by adjusting gene activity rather than blocking a drug target in the body. It may be a complementary approach alongside standard treatment. In Russian clinical practice, peptide bioregulators are often used with conventional medicines. If you have moderate-to-severe BPH, stay on your prescribed treatment and discuss any add-on approach with your urologist.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Vesilute research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Vesilute is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek